Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) is a single-inhaler triple therapy for the long-term, maintenance treatment of patients with chronic obstructive pulmonary disease.
Thomas Castles
Advertisement
Articles by Thomas Castles
Tymlos, an injection that treats postmenopausal women with osteoporosis, may incrase the risk of osteosarcoma.
Cholesterol-lowering drug approved in once-monthly 300 mg dosing option.
Advertisement
Latest Updated Articles
Monthly PCSK9 Inhibitor Injection Gets FDA ApprovalPublished: April 27th 2017 | Updated:
Newly Approved Osteoporosis Drug Carries Cancer RiskPublished: May 2nd 2017 | Updated:
Once-Daily COPD Triple Therapy Gets FDA ApprovalPublished: September 19th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Addressing Burnout in Pharmacy Residency: A Comprehensive Approach to Enhancing Well-Being
4
CHEST 2025: Advancing Respiratory Virus Vaccines and Improving Uptake Among High-Risk Populations
5
